TABLE 1.

Change from baseline in primary and selected secondary end-points with riociguat and placebo in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial (CHEST)-1 study

End-point	Placebo			Riociguat			p-value#
	Patients	Baseline	Change	Patients	Baseline	Change
Primary end-point
6MWD m	88	356±75	–6±84	173	342±82	39±79	<0.001
Selected secondary end-points
PVR dyn·s·cm–5	82	779±401	23±274	151	791±432	–226±248	<0.001
NT-proBNP pg·mL−1	73	1706±2567	76±1447	150	1508±2338	–291±1717	<0.001
WHO-FC	87	Class I: 0 Class II: 25 (29%) Class III: 60 (69%) Class IV: 2 (2%)	13 (15%) moved to lower class; 68 (78%) stayed the same; 6 (7%) moved to higher class	173	Class I: 3 (2%) Class II: 55 (32%) Class III: 107 (62%) Class IV: 8 (5%)	57 (33%) moved to lower class; 107 (62%) stayed the same; 9 (5%) moved to higher class	0.003

Data are presented as n or mean±sd, unless otherwise stated. 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; NT-proBNP: N-terminal pro-brain natriuretic peptide; WHO-FC: World Health Organization functional class. ^#: calculated with the use of stratified Wilcoxon test for the change from baseline to last visit. Reproduced and modified from [26] with permission from the publisher.